ArticleOncogene2002
Src kinase contributes to the metastatic spread of carcinoma cells.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 118 citations in OpenAlex.
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecologic oncology · 2012Trial
- A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.Investigational new drugs · 2012Trial
- Ole-4, a novel synthetic derivative of Oleuropein, enhances antitumor immunity and modulates kinase activity-dependent signaling.Journal of translational medicine · 2026Article
- Text-Mining Approach to Identify Hub Genes of Cancer Metastasis and Potential Drug Repurposing to Target Them.Journal of clinical medicine · 2022Article
- Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop.Cell death & disease · 2021Article
- Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs.Molecules (Basel, Switzerland) · 2020Review
- Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas.BMC veterinary research · 2020Article
- Osteoclast Signal Transduction During Bone Metastasis Formation.Frontiers in cell and developmental biology · 2020Review
- Regulation of transforming growth factor β-mediated epithelial-mesenchymal transition of lens epithelial cells by c-Src kinase under high glucose conditions.Experimental and therapeutic medicine · 2018Article
- Article
- An mRNA-specific tRNAi carrier eIF2A plays a pivotal role in cell proliferation under stress conditions: stress-resistant translation of c-Src mRNA is mediated by eIF2A.Nucleic acids research · 2017Article
- Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.BMC research notes · 2016Article
- Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.PloS one · 2016Article
- The importance of Src signaling in sarcoma.Oncology letters · 2015Article
- Article
- miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.Asian journal of andrology · 2013Article
- Src-signaling interference impairs the dissemination of blood-borne tumor cells.Cell and tissue research · 2012Article
- Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.The Journal of biological chemistry · 2011Article
- Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility.BMC cell biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The involvement of Src kinase during carcinoma metastasis has been explored by using the NBT-II rat carcinoma cell line, which can be induced to scatter in vitro through Src activity. Here we show that Src activity was not required for growth of tumors derived from NBT-II cells injected into nude mice. In contrast, the presence of micrometastases was strictly dependent on Src, since the percentage of mice bearing metastases was dramatically reduced by the expression of a dominant-negative mutant of Src (SrcK-) or of Csk, the natural inhibitor of Src. Furthermore, metastatic cells originating from NBT-II cells displayed a Src activity higher than the parental cells, confirming that Src gives a selective advantage during the metastatic process. Finally, anatomopathological analysis of the primary tumors arising from NBT-II cells expressing Csk or SrcK- constructs revealed a highly differentiated epithelial phenotype contrasting with the poor differentiation of tumors derived from parental cells. The differentiated phenotype correlated with the presence of desmosomes at the cell periphery and the absence of vimentin intermediate filaments. Altogether, these data demonstrate that Src activity correlates with the loss of epithelial differentiation concomitantly with the increase of the metastatic potential of carcinoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.